| DIRECT COMPETITOR COMPARISON | |
| CYTR | AOLS.OB | CELG | SNY | Industry | | Market Cap: | 104.01M | 11.99M | 25.48B | 99.12B | 104.07M | | Employees: | 31 | 1 | 2,441 | 98,213 | 68 | | Qtrly Rev Growth (yoy): | 657.90% | N/A | 17.30% | 8.50% | 19.70% | | Revenue (ttm): | 10.83M | N/A | 2.56B | N/A | 14.01M | | Gross Margin (ttm): | 100.00% | N/A | 91.04% | 75.20% | 65.67% | | EBITDA (ttm): | -6.20M | N/A | 573.33M | N/A | -12.30M | | Oper Margins (ttm): | -63.11% | N/A | 16.83% | N/A | -149.46% | | Net Income (ttm): | -5.87M | -2.61M | 373.27M | N/A | N/A | | EPS (ttm): | -0.061 | -0.078 | 0.802 | N/A | -0.33 | | P/E (ttm): | N/A | N/A | 69.14 | N/A | 16.37 | | PEG (5 yr expected): | N/A | N/A | 1.12 | 2.59 | 1.31 | | P/S (ttm): | 9.61 | N/A | 9.97 | N/A | 9.43 |
|
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 56.35 | 0.00% | 57.03B | 12.29 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 46.94 | 0.00% | 13.57B | 15.71 | | Genzyme Corp. | GENZ | 50.70 | 0.00% | 13.45B | 28.91 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.11 | 0.00% | 41.50B | 17.83 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 49.78 | 0.00% | 8.88B | 1015.92 | | Teva Pharmaceutical Industries Limited | TEVA | 52.79 | 0.00% | 46.51B | 48.30 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 37.09 | 0.00% | 3.94B | 19.12 | | Barr Pharmaceuticals, Inc. | Private - View Profile | | King Pharmaceuticals Inc. | KG | 11.83 | 0.00% | 2.94B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 17.87 | 0.00% | 5.46B | 109.63 | | Pfizer Inc. | PFE | 18.17 | 0.00% | 146.62B | 15.09 | | Johnson & Johnson | JNJ | 62.84 | 0.00% | 173.38B | 13.72 | | GlaxoSmithKline plc | GSK | 41.47 | 0.00% | 105.13B | 13.17 | | Sanofi-Aventis | SNY | 37.96 | 0.00% | 99.12B | N/A |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Novartis AG | NVS | 55.60 | 0.00% | 126.28B | 16.65 | | RHHBY.PK | 40.92 | 0.00% | N/A | N/A | | AstraZeneca plc | AZN | 44.83 | 0.00% | 65.00B | 9.00 | | Abbott Laboratories | ABT | 54.49 | 0.00% | 84.28B | 14.76 | | Bristol-Myers Squibb Co. | BMY | 25.31 | 0.00% | 50.14B | 13.09 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | SNY | | Cramer: Dubai Debt Can't Sink These 6 Dividend Stocks
Mon 6:38pm -
at CNBC | | • | SNY | | [video] Dividend & Conquer
Mon 6:00pm -
at CNBC | | • | CELG | | Celgene: New Studies Expected to Boost Sales
Mon 5:35pm -
at Seeking Alpha | | • | SNY | | Making Money More Efficiently
Mon 3:25pm -
at Motley Fool | | • | SNY | | Van Berkom And Associates Prices Health Care And Industrial Companies
Mon 1:37pm -
Wall Street Transcript | | • | SNY | | Vaccines: Hopes of prevention receive shot in the arm
Mon 12:20pm -
at FT.com | | • | CELG | | Johnson & Johnson: Good & Bad News
Mon 10:47am -
at TheStreet.com | | • | CELG | | 13 Biotechs to Watch for at Hematology Conference
Mon 4:47am -
at Seeking Alpha | | • | CELG | | Celgene Corporation to Present at the NASDAQ OMX 23rd Investor Program
Fri, Nov 27 -
Business Wire | | • | CELG | | Dream Stocks for Biotech Investors
Wed, Nov 25 -
at Motley Fool | | • | CELG | | Beware the Second Leg of the Next Great Recession
Mon, Nov 23 -
at Motley Fool | | • | CELG | | Yale Endowment Prefers ETFs, Selected Equities
Fri, Nov 20 -
Indie Research | | • | AOLS.OB | | Duke University Initiates Study of AEOL 10150 to Measure Compound's Ability to Protect Healthy Tissue in Mice Receiving Chemotherapy and Radiation for Non-Small Cell Lung Cancer
Tue, Nov 17 -
Business Wire | | • | AOLS.OB | | Data Demonstrating Aeolus Pharmaceuticals' AEOL 10150's Efficacy as a Broad Spectrum Countermeasure Against Radiological and Chemical Threats Presented at the GHSI Public Health Emergency Medical Countermeasures Workshop
Thu, Nov 5 -
Business Wire | | • | AOLS.OB | | Aeolus Pharmaceuticals' AEOL 10150 Protects Lungs Against Chlorine Gas Exposure in Animal Studies
Wed, Nov 4 -
Business Wire | | • | AOLS.OB | | CEO Interview: Aeolus Pharmaceuticals, Inc. - John L. McManus
Mon, Nov 2 -
Wall Street Transcript | | • | AOLS.OB | | Aeolus Drug Protects the Gastrointestinal Tract in Acute Radiation Syndrome Studies Sponsored by the National Institutes of Health's National Institute for Allergy and Infectious Diseases
Thu, Oct 22 -
Business Wire | | | All Headlines for these symbols... |
|
|
|
0.34% Nasdaq 0.00%
Competitors
